Neoplasm – HOME

AI Model Fusion Improves Preoperative Ovarian Cancer Diagnosis Accuracy

A new diagnostic approach using fused machine learning models shows promise in improving preoperative classification of ovarian tumors. The integrated system combines blood test analysis with MRI interpretation to help distinguish between borderline and malignant cases.

Breakthrough in Ovarian Tumor Diagnosis

Researchers have developed an innovative artificial intelligence approach that reportedly improves preoperative classification accuracy for ovarian tumors, according to recent findings published in Scientific Reports. The multimodal integration method combines machine learning analysis of blood tests with deep learning interpretation of MRI scans to better distinguish between borderline ovarian tumors (BOTs) and malignant ovarian tumors (MOTs) before surgery.

by Natalie BrooksOctober 23, 2025

Anomalies and Alternative Science Scientific Research

Researchers Establish Six Novel Biliary Tract Cancer Cell Lines for Advanced Biomedical Study

Researchers have successfully established six new human biliary tract cancer cell lines, marking a significant advancement for cancer research. These cell lines enable detailed investigation into genetic mutations and molecular mechanisms driving this challenging disease. The development promises to accelerate understanding of biliary tract cancer biology and potential therapeutic targets.

Breakthrough in Biliary Cancer Research

Researchers have reportedly established six new human biliary tract cancer cell lines, according to recent scientific reports. This development represents a significant advancement for studying cholangiocarcinoma and related cancers, which have historically had limited research tools available. Sources indicate these cell lines will enable more comprehensive investigation into the biological nature of this aggressive disease.

by Darren HoltOctober 18, 2025

Biotechnology Healthcare Technology

Circle Pharma to Present Cyclin D1 RxL Inhibition Data Showing Anti-Tumor Potential at Major Cancer Conference

Circle Pharma will present promising preclinical data on its first-in-class oral macrocyclic cyclin D1-selective inhibitors at the upcoming AACR-NCI-EORTC conference. The company’s innovative approach targets cyclin D1-driven cancers through selective disruption of the cyclin D1-Rb interaction.

Circle Pharma, a clinical-stage biopharmaceutical company focused on developing targeted macrocycle therapeutics, has announced an upcoming poster presentation highlighting the significant anti-tumor potential of cyclin D1 RxL inhibition. The presentation will occur at the prestigious AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from October 22-26, 2025.